Researchers from IOCB Prague have discovered a new type of substances capable of safely transporting various types of nucleic acids used for therapeutic purposes into cells, from basic building blocks ...

The two most successful coronavirus vaccines developed in the U.S. – the Pfizer and Moderna vaccines – are both mRNA vaccines. The idea of using genetic material to produce an immune response has ...

Lipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA products (mRNA), most notably used for vaccine production against the recent SARS-CoV-2 pandemic. In this ...

Nucleic acid technology came of age during COVID-19 with biopharma firms developing, testing, mass producing, and shipping mRNA vaccines in record time. However, as the pandemic ebbs, the industry now ...

An analysis of patient records suggests that mRNA covid-19 vaccines boost the immune response to cancerous tumours when given ...

Two biotechs are teaming up to deliver cholesterol-busting mRNA to clogged arteries. Syracuse, New York-based Repair Biotechnologies will use Swiss company Genevant’s lipid nanoparticles to usher its ...

Piezo Therapeutics has emerged as the latest startup focused on the delivery of nucleic acids, launching with $2 million in seed funding and a platform that combines electric pulses and microneedles.

San Diego CDMO TriLink BioTechnologies is reducing its headcount while its parent company, Maravai LifeSciences, moves forward with a broader restructuring plan. TriLink is letting go of 69 employees ...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an ...

A multi-institutional team led by University of Washington scientists have engineered a new vaccine platform combining mRNA ...